Sanofi-Aventis Cvr (GCVRZ) 0.64 $GCVRZ
Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - Seeking Alpha - Thu Feb 12, 3:43AM CST
Originally Published on November 28, 2014 Lessons from the Recent Years and Opportunities for the Years to Come Chris DeMuth Jr It's not given to human beings to have such talent that they can just know everything about everything all the time....
OSHC: 14.07 (-0.06), LORL: 71.94 (+0.15), PFN: 10.19 (+0.01), QLTI: 4.15 (unch), DTV: 87.51 (-0.32), GPT: 6.83 (+0.04), GCVRZ: 0.64 (-0.01)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Sanofi Rights - Is A $13 Payout Even Possible?
Anthony Cataldo - at Seeking Alpha - Wed Dec 10, 12:44PM CST
GCVRZ: 0.64 (-0.01)
Sanofi Rights Remain Overpriced And Drift Lower: The Market Is Efficient
Anthony Cataldo - at Seeking Alpha - Wed Dec 03, 6:31AM CST
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Wall Street Breakfast: Moody's Downgrades Japan's Sovereign Debt Rating
Wall Street Breakfast - Seeking Alpha - Mon Dec 01, 5:32AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Short idea on ...
AMX: 21.97 (+0.27), SNE: 27.30 (+0.19), WMT: 85.81 (-0.08), INTC: 34.36 (+0.23), GOOG: 549.01 (+6.08), VIV: 18.95 (+0.51), SPY: 209.78 (+0.86), TGT: 76.12 (-0.75), GOOGL: 551.16 (+5.15), FEYE: 42.26 (+2.63), OIBR: 2.49 (+0.34), AGCO: 49.78 (+0.97), GCVRZ: 0.64 (-0.01), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), PT: 0.83 (+0.04), TSU: 22.74 (+0.66), QQQ: 106.91 (+0.91), AZN: 69.96 (+0.20), TXN: 57.97 (+0.53)
Sanofi Rights - Is GCVRZ Underpriced Or Is The Market Efficient?
Anthony Cataldo - Seeking Alpha - Mon Dec 01, 5:31AM CST
Disclosure: The author remains long more than 20,000 shares of GCVRZ, but may sell and or trade this CVR. After purchasing 80,000 shares at an average cost of $0.315 less than 12 months ago, 60,000 shares were sold for $0.85 on November 28, 2014,...
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Today In SA PRO: Wednesday, November 26
SA PRO Top Ideas - at Seeking Alpha - Thu Nov 27, 4:00AM CST
Top Idea: AGCO Corporation by Thomas Clark: Long / Mid-Cap / Farm & Construction Machinery / Value / Temporary Headwinds / Margin Expansion / Share Buyback / New Author / 40%+ Upside Top Idea: Sanofi-Aventis Value Right by Chris DeMuth,...
MAG: 40.68 (-0.20), AGCO: 49.78 (+0.97), GCVRZ: 0.64 (-0.01), ORAN: 18.52 (+0.07)
Best Idea For 2014: Sanofi Rights Post-FDA Approval
Chris DeMuth Jr. - at Seeking Alpha - Thu Nov 27, 4:00AM CST
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), GCVRZ: 0.64 (-0.01), TEVA: 56.77 (-0.58), SNY: 49.42 (+0.82), NVS: 102.20 (-0.17)
CVRs on Lemtrada +135% following approval
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:19AM CST
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Genzyme's Lemtrada approved by the FDA
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:47PM CST
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
One More Time: The Genzyme Contingent Value Right
Ruerd Heeg - Seeking Alpha - Wed Oct 29, 9:15AM CDT
The Genzyme Contingent Value Right (NASDAQ: GCVRZ ) is a bet on Genzyme's sales of MS drug Lemtrada, also called alemtuzumab. The drug is the most efficacious MS drug to date. It has some serious side effects which are remediable with proper...
BIIB: 391.66 (-0.45), GCVRZ: 0.64 (-0.01)
Market Maker Surveillance Report. BSX, SMA, EMC, BX, GCVRZ, PFMT, Bullishly Biased Price Friction For Thursday, September 11th 2014
M2 - Fri Sep 12, 4:16AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4878 companies with "abnormal" market making, 2401 companies with positive Friction Factors and 2459 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Boston Scientific Corp (NYSE:BSX), Symmetry Medical Inc (NYSE:SMA), EMC Corp (NYSE:EMC), BIOX Corp (NYSE:BX), Sanofi SA (NASDAQ:GCVRZ), (NYSE
FMT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BSX: 14.98 (+0.24), SMA: 9.27 (-0.04), BX: 37.40 (+0.49), PFMT: 6.02 (-0.02), GCVRZ: 0.64 (-0.01), EMC: 27.99 (+0.12)
Market Maker Surveillance Report. BAC, GE, MRVL, USB, WFC, GCVRZ, Bullishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. BANK OF AMERICA CORPORATION (NYSE:BAC), General Electric Co (NYSE:GE), Marvell Technology Group Ltd (NASDAQ:MRVL), U.S. Bancorp (NYSE:USB), WELLS FARGO & COMPANY (NYSE:WFC), Sanofi SA (NASDAQ:GCVRZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GE: 25.15 (+0.26), USB: 45.07 (-0.05), MRVL: 16.59 (+0.08), GCVRZ: 0.64 (-0.01), WFC: 55.33 (+0.47), BAC: 16.61 (-0.06)
Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - Seeking Alpha - Thu Feb 12, 3:43AM CST
Originally Published on November 28, 2014 Lessons from the Recent Years and Opportunities for the Years to Come Chris DeMuth Jr It's not given to human beings to have such talent that they can just know everything about everything all the time....
OSHC: 14.07 (-0.06), LORL: 71.94 (+0.15), PFN: 10.19 (+0.01), QLTI: 4.15 (unch), DTV: 87.51 (-0.32), GPT: 6.83 (+0.04), GCVRZ: 0.64 (-0.01)
CVRs - The Good, The Bad And The Ugly
Chris DeMuth Jr. - at Seeking Alpha - Wed Feb 11, 12:40AM CST
AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), VRX: 167.00 (-0.50), KR: 72.86 (+0.41), SWY: 35.10 (-0.04), GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Sanofi Rights - Is A $13 Payout Even Possible?
Anthony Cataldo - at Seeking Alpha - Wed Dec 10, 12:44PM CST
GCVRZ: 0.64 (-0.01)
Sanofi Rights Remain Overpriced And Drift Lower: The Market Is Efficient
Anthony Cataldo - at Seeking Alpha - Wed Dec 03, 6:31AM CST
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Wall Street Breakfast: Moody's Downgrades Japan's Sovereign Debt Rating
Wall Street Breakfast - Seeking Alpha - Mon Dec 01, 5:32AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Short idea on ...
AMX: 21.97 (+0.27), SNE: 27.30 (+0.19), WMT: 85.81 (-0.08), INTC: 34.36 (+0.23), GOOG: 549.01 (+6.08), VIV: 18.95 (+0.51), SPY: 209.78 (+0.86), TGT: 76.12 (-0.75), GOOGL: 551.16 (+5.15), FEYE: 42.26 (+2.63), OIBR: 2.49 (+0.34), AGCO: 49.78 (+0.97), GCVRZ: 0.64 (-0.01), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), PT: 0.83 (+0.04), TSU: 22.74 (+0.66), QQQ: 106.91 (+0.91), AZN: 69.96 (+0.20), TXN: 57.97 (+0.53)
Sanofi Rights - Is GCVRZ Underpriced Or Is The Market Efficient?
Anthony Cataldo - Seeking Alpha - Mon Dec 01, 5:31AM CST
Disclosure: The author remains long more than 20,000 shares of GCVRZ, but may sell and or trade this CVR. After purchasing 80,000 shares at an average cost of $0.315 less than 12 months ago, 60,000 shares were sold for $0.85 on November 28, 2014,...
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Today In SA PRO: Wednesday, November 26
SA PRO Top Ideas - at Seeking Alpha - Thu Nov 27, 4:00AM CST
Top Idea: AGCO Corporation by Thomas Clark: Long / Mid-Cap / Farm & Construction Machinery / Value / Temporary Headwinds / Margin Expansion / Share Buyback / New Author / 40%+ Upside Top Idea: Sanofi-Aventis Value Right by Chris DeMuth,...
MAG: 40.68 (-0.20), AGCO: 49.78 (+0.97), GCVRZ: 0.64 (-0.01), ORAN: 18.52 (+0.07)
Best Idea For 2014: Sanofi Rights Post-FDA Approval
Chris DeMuth Jr. - at Seeking Alpha - Thu Nov 27, 4:00AM CST
BIIB: 391.66 (-0.45), PFE: 34.64 (-0.23), GCVRZ: 0.64 (-0.01), TEVA: 56.77 (-0.58), SNY: 49.42 (+0.82), NVS: 102.20 (-0.17)
CVRs on Lemtrada +135% following approval
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:19AM CST
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
Genzyme's Lemtrada approved by the FDA
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 8:47PM CST
GCVRZ: 0.64 (-0.01), SNY: 49.42 (+0.82)
One More Time: The Genzyme Contingent Value Right
Ruerd Heeg - Seeking Alpha - Wed Oct 29, 9:15AM CDT
The Genzyme Contingent Value Right (NASDAQ: GCVRZ ) is a bet on Genzyme's sales of MS drug Lemtrada, also called alemtuzumab. The drug is the most efficacious MS drug to date. It has some serious side effects which are remediable with proper...
BIIB: 391.66 (-0.45), GCVRZ: 0.64 (-0.01)
Market Maker Surveillance Report. BSX, SMA, EMC, BX, GCVRZ, PFMT, Bullishly Biased Price Friction For Thursday, September 11th 2014
M2 - Fri Sep 12, 4:16AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4878 companies with "abnormal" market making, 2401 companies with positive Friction Factors and 2459 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. Boston Scientific Corp (NYSE:BSX), Symmetry Medical Inc (NYSE:SMA), EMC Corp (NYSE:EMC), BIOX Corp (NYSE:BX), Sanofi SA (NASDAQ:GCVRZ), (NYSE
FMT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . BSX: 14.98 (+0.24), SMA: 9.27 (-0.04), BX: 37.40 (+0.49), PFMT: 6.02 (-0.02), GCVRZ: 0.64 (-0.01), EMC: 27.99 (+0.12)
Market Maker Surveillance Report. BAC, GE, MRVL, USB, WFC, GCVRZ, Bullishly Biased Price Friction For Thursday, September 4th 2014
M2 - Fri Sep 05, 3:10AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4751 companies with "abnormal" market making, 1909 companies with positive Friction Factors and 3133 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bullish bias) in their stock prices. This means that there was more selling than buying in the stocks and their stock prices rose. BANK OF AMERICA CORPORATION (NYSE:BAC), General Electric Co (NYSE:GE), Marvell Technology Group Ltd (NASDAQ:MRVL), U.S. Bancorp (NYSE:USB), WELLS FARGO & COMPANY (NYSE:WFC), Sanofi SA (NASDAQ:GCVRZ). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
GE: 25.15 (+0.26), USB: 45.07 (-0.05), MRVL: 16.59 (+0.08), GCVRZ: 0.64 (-0.01), WFC: 55.33 (+0.47), BAC: 16.61 (-0.06)
